Drug Information

Drug (ID: DG00034) and It's Reported Resistant Information

Name	Abiraterone
Synonyms	Abiraterone (AR inhibitor) Click to Show/Hide
Indication	In total 1 Indication(s) Prostate cancer [ICD-11: 2C82] Approved [1]
Structure
Drug Resistance Disease(s)	Disease(s) with Clinically Reported Resistance for This Drug (1 diseases) Prostate cancer [ICD-11: 2C82] [1]
Target	Steroid 17-alpha-monooxygenase (S17AH)	CP17A_HUMAN	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	C24H31NO
IsoSMILES	C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O
InChI	1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
InChIKey	GZOSMCIZMLWJML-VJLLXTKPSA-N
PubChem CID	132971
ChEBI ID	CHEBI:68642
TTD Drug ID	D02STN
DrugBank ID	DB05812

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Prostate cancer [ICD-11: 2C82]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)		Click to Show/Hide
Key Molecule: Androgen receptor (AR)			[1]
Molecule Alteration	Structural variation	Copy number gain	Molecule Info
Resistant Disease	Prostate cancer [ICD-11: 2C82.0]		Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Whole genome sequencing assay; Exome sequencing assay
Mechanism Description	Accordingly, AR amplification was detected in circulating cell-free DNA and was shown to be associated with enzalutamide and abiraterone treatment resistance in a cohort of 62 CRPC patients.
Key Molecule: Androgen receptor (AR)			[1]
Molecule Alteration	Structural variation	Copy number gain	Molecule Info
Resistant Disease	Primary prostate cancer [ICD-11: 2C82.Z]		Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	Whole genome sequencing assay; Exome sequencing assay
Mechanism Description	Accordingly, AR amplification was detected in circulating cell-free DNA and was shown to be associated with enzalutamide and abiraterone treatment resistance in a cohort of 62 CRPC patients.

References

Ref 1	Clonal origin and spread of metastatic prostate cancer. Endocr Relat Cancer. 2016 Apr;23(4):R207-17. doi: 10.1530/ERC-16-0049. Epub 2016 Mar 21.